Banner Pharmacy Services, LLC, Chandler, AZ
Is Banner Pharmacy Services, LLC registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility, with FDA’s note “De-registered as an Outsourcing Facility”.
Does Banner Pharmacy Services, LLC hold a Arizona pharmacy license?
State board of pharmacy records for Arizona are not checked: the board’s website, which hosts its license verification and board orders, answers automated requests with a bot challenge, and this index does not work around blocks.
Has Banner Pharmacy Services, LLC had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 state referral letter (Apr 9, 2020) and 1 FMD-145 letter (Apr 9, 2020) for Banner Pharmacy Services, LLC. State board of pharmacy records for Arizona are not checked: the board’s website, which hosts its license verification and board orders, answers automated requests with a bot challenge, and this index does not work around blocks. The state referral and handoff letters above are FDA’s letters to the state, not board actions.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Banner Pharmacy Services, LLC
- Location
- Chandler, AZ
- Type as FDA labels it
- 503A
- FDA’s note
- De-registered as an Outsourcing Facility
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 1
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Apr 9, 2020
- FDA Data Dashboard inspections
- 3 inspections: 1 OAI, 1 VAI, 1 NAI; 4 published Form 483s
- Form 483 text on this page
- 3 Form 483s, 27 observations
- State board records
- Not checked
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Banner Pharmacy Services, LLC, a 503A facility, with 3 dated actions.
| Document | |||
|---|---|---|---|
| Apr 9, 2020 | FMD-145 letter | FMD-145 Letter Issued 04/09/2020 | FDA copy (archived) |
| Apr 9, 2020 | State referral letter | Referral Letter to the Arizona State Board of Pharmacy Issued 04/09/2020 | FDA copy (archived) |
| Oct 8, 2019 | Form 483 | 483 Issued 10/08/2019 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Banner Pharmacy Services, LLC, Chandler, AZ (FEI number 3009422393), matched to this page by exact name, city and state. It lists 3 inspections: 1 OAI, 1 VAI, 1 NAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Oct 8, 2019 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3009422393 | 1105805 |
| Mar 20, 2015 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3009422393 | 919292 |
| Mar 5, 2014 | No Action Indicated (NAI) | Drug Quality Assurance (Drugs) | 3009422393 | 869432 |
Form 483s FDA has published for this site
- Oct 8, 2019: Form 483 to Banner Pharmacy Services, LLC, published Dec 9, 2019. fda.gov
- Nov 20, 2017: Form 483 to Banner Pharmacy Services, LLC, published Jan 17, 2024. fda.gov
- Nov 20, 2017: Form 483 to Banner Pharmacy Services, LLC, published Jan 17, 2024. fda.gov
- Jul 23, 2015: Form 483 to Banner Pharmacy Services, LLC, published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 27 numbered observations in all, across 3 inspections ending Sep 20, 2017 to Oct 8, 2019. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Oct 2, 2019 to Oct 8, 2019: 1 observation
- Firm on the cover
- , Chandler, AZ 85226-2410
- FEI number
- 3009422393
- Establishment type on the cover
- Producer of Sterile Drug Products
- FDA district office on the cover
- 19701 Fairchild Irvine, CA 92612-2445
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Disinfecting agents and used in the ISO 5 classified aseptic processing areas were not sterile.
Specifically,
Per SOP 02-04.02 "Cleaning and Disinfecting of the Sterile Compounding Area" deaning agents used in the ISO classified work areas are described as an <Redacted B4> or <Redacted B4> however, during review of the cleaning agent ' <Redacted B4> , it was confirmed the agent is not sterile.
Inspection Sep 11, 2017 to Sep 20, 2017: 13 observations
- Firm on the cover
- Banner Pharmacy Services, LLC, 7300 W Detroit St, Chandler, AZ 85226-2410
- FEI number
- 3009422393
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 19701 Fairchild Irvine, CA 92612-2445
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
The quality control unit lacks the responsibility and authority to approve and reject all drug products.
Specifically,
Your firm failed to reject batches of sterile drug product that did not meet specifications for potency and particulate matter. The following drug products failed potency or particulate matter testing and were released for distribution without adequate justification for invalidating failing test results:
Lot Number
Drug Product Date Released
Test Failed
062817S2 Magnesium Sulfate 10g added to Lactated Ringers 250mL bag
8/14/2017 Particulate Matter
071417Sl Norepinephrine Bitaitrate 8mg added to 0.9% Sodium Chloride 250mL bag
8/7/2017 Particulate Matter
071417S2 Oxytocin 30 units added to 0.9% Sodium Chloride 500mL bag
8/23/2017 Potency
071717Sl Oxytocin 30 units added to 0.9% Sodium Chloride 500mL bag
8/23/2017 Potency
072017S4 Oxytocin 30 units added to 0.9% Sodium Chloride 500mL bag
8/23/2017 Potency
Observation 2
Results of stability testing are not used in determining expiration dates.
Specifically,
Your firm's beyond-use dates (BUD) for sterile drug products are not assigned based on adequate stability testing. We reviewed stability study lots and observed DOS results for potency at one or more time points. Your firm assigned BUD based only on the passing results and disregarded the data from failing lots. For example:
• Oxytocin 30 units in 500ml NS current BUD of 119 days was based on one (1) product lot that had potency testing data within specification at all time points. However, three (3) additional lots on stability were out of specification for potency on days 36, 45, and 113.
• Lidocaine HCL 1 % buffered has a current BUD of 45 days. However, while one (1) lot is still under testing, three (3) lots on stability were out of specification for potency on days 14, 45, and 60.
• Midazolam 100 MG (1 MG/ML) in 0.9% Sodium Chloride 100 ML Cassette current BUD of 180 days was based on one (1) product lot that had potency testing data within specification at all time points. However, a second product lot on stability was out of specification for potency on day 120 of the study.
Observation 3
Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.
Specifically,
A. On September 13, 2016, your firm's <Redacted B4> testing of your cleanroom revealed there were leaks in 1 of the HEPA filters in the ISO 7 non-hazardous compounding room and 1 of the <Redacted B4> HEPA filters in the ISO 8 anteroom (gowning area). These leaks were documented again during the March 2017 <Redacted B4> certification testing. The two leaking HEPA filters were replaced on August 3, 2017. Your firm continued to manufacture sterile drug products from September 13, 2016 until August 3, 2017 and did not perform an investigation to determine if the leaking HEPA filters would compromise the sterility of your drug products.
B. Your firm's March 2017 cleamoom testing revealed the ISO 7 non-hazardous compounding room and anteroom (gowning area) did not meet the compendial pressure differential criteria of +0.02" of water. ...
Observation 4
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.
Specifically,
A. Your firm utilizes <Redacted B4> a sporicidal cleaning disinfectant for <Redacted B4> cleaning of the ISO 5 laminar flow hoods, ISO 7 non-hazardous compounding room, ISO 8 anteroom (gowning room), and ISO 8 prep area. Your fnm does not have scientific data to ensure the cleaning solution is effective as a sporicidal disinfectant.
B. Your firm failed to perform cleaning in the ISO 7 non-hazardous compounding room after loss ofpositive pressure was observed as required per your SOP entitled, "Clean Room Downtime". The SOP states "If airflow or pressures out ofrange for greater than <Redacted B4> and "Down for less than <Redacted B4> clean". On the following days, your fnm failed to follow procedures and perform cleaning required following a loss of pressure:
Date Total time with lost pressure Cleaning Performed per Clean Room Downtime SOP May 25, 2017 Up to 6 hours and 12 minutes
No (Cleaning with[(l5) (4) I f(l5) (4) I) May 25, 2017 Up to 23 minutes ((l5) (4) I)
~(l5) (4) I)
No cleaning perfo1med ...
Observation 5
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.
Specifically,
A. On 9/11/2017, we observed Technician <Redacted B4> performing aseptic processing of Lidocaine HCl, Oxytocin, and Vancomycin sterile drug products. We observed all <Redacted B4> technicians entering and leaving the ISO 5 Laminar Flow Hood (LFH) multiple times without sanitizing their gloved hands during the production of these sterile drug products.
B. We also observed all <Redacted B4> technicians introducing items such as 0.9% Sodium Chloride 500mL bags and J-Tip Syringes into the ISO 5 LFH without sanitizing the items or their outer packaging. In addition, your firm removes sterile items including Sodium Chloride 500mL bags and <Redacted B4> medication cassette reservoirs from their outer packaging in the ISO 8 prep room.
C. Not all of your technicians are qualified to perfom aseptic drug production as only 2 out of a total of <Redacted B4> technicians have performed media fills that simulated the most complex or high volume compounding processes under normal operating conditions.
D. ...
Observation 6
Clothing of personnel engaged in the manufacturing and processing of drug products is not appropriate for the duties they perform.
Specifically,
C. Your fnm's gowning practices are inadequate to prevent contamination of sterile gowning
materials. On 9/12/2017, we observed 4 (bH Y technicians in the anteroom gowning at the same time. The technicians were observed walking in the ISO 8 anteroom/gowning area with non sterile shoe covers, donning sterile shoe covers, and then walking in the same area. We observed one technician who had donned a sterile gown bump into another technician who was in his scrnbs. The technician did not re-gown. These technicians were gowning in order to perfo1m
4 (b) ( ) cleaning operations for the ISO 7 non-hazardous compounding area. In addition, your fnm
does not have an occupancy limit for the gowning anteroom.
D. Your fnm stores laundered scrnbs in the restrooms/changing rooms in front of the bathroom
stalls. On 9/18/2017, we observed the door to the scrnb storage unit in the men 's restroom was opened. These scrnbs are worn by technicians underneath their sterile gowns while perfo1ming aseptic operations.
E. ...
Observation 7
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically,
G. Your fnm does not perfo1m non-viable paiiiculate air monitoring in the ISO-classified areas during aseptic processing ofsterile diug products. Non-viable air sampling is only conducted during[(6) (4) I certification of your cleamoom.
H. Your fnm does not routinely monitor all ISO-classified areas in your facility. For example, the ISO 8 Prep Room '(bH4Yis not sampled for viable air or viable surface. Also, non-viable air sampling for ISO 8 Prep Room lbl (4l is only performed during the (6) (4) Ice1iification. We observed sterile items, such as 0.9% sodium chloride injection USP 500 ml IV bags an~~(o) (4) medication cassette reservoirs were removed from their outer packaging in Prep Room r<bH4l and placed in a non-sterile plastic tote. These items were later transfeITed to the ISO 5 LFH for production without any fmi her sanitization of these items.
I. Sampling of operator gowns is not perfo1med after daily operations but is instead perfo1m ed once every[( I::>) (4) Iper operator prior to production activities on that day.
J. ...
Observation 8
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been aheady distributed.
Specifically,
0 . Your fnm's environmental monitoring excursion investigations are inadequate. For example, your fnm does not identify a probable root cause and does not assess product impact. Additionally, your investigations lack info1mation stating when the investigations were open, closed, and who perfo1med the investigations. Also, not all investigations have been reviewed and approved. Examples of investigations include but are not limited to:
4 a. On 5/26/2016, ISO 5 (o) < L Hood !tiH'viable active air was sampled and one (1) cfu was
repo1ied. On 6/13/2016, the contract testing lab notified your fnm that speciation dete1mined the colony to be Gram negative non-enteric bacteria and your fnm' s CAP A stated, "As per USP <797>, the gram negatives, yeast and mold are considered highly pathogenic and can be fatal to patients, especially immune compromised patients, receiving CSP's". [(6) (.2J)l product lots had been compounded in Hood !tiH• from 5/26/2016 to 6/13/2016.
b. ...
Observation 9
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications prior to release.
Specifically,
Your firm produces non-sterile oral Vancomycin HCL 250 mg/10 ml and GI cocktail oral suspension 30 ml (20 ml Maalox plus equiv + 10 ml 2% Lidocaine) for office use. Your firm has not established acceptable levels of microorganisms and has not tested these finished drug products for acceptable levels and the presence of objectionable microorganisms per compendial requirements.
Observation 10
Test procedures relative to appropriate laboratory testing for pyrogens are not written and followed.
Specifically, your firm's endotoxin testing is deficient in that only five (5) out of a total of fifteen (15) sterile compounded drug products have complete endotoxin method validations per compendia! requirements.
Observation 11
Determinations of conformance to appropriate written specifications for acceptance are deficient for drug products.
Specifically,
Your firm does not perform 100% visual inspection of all sterile drug products. Your firm's technicians/pharmacists perform cursory batch inspection followed by detailed visual inspections on <Redacted B4> that batch. Visual inspections are performed without the use of contrasting backgrounds and a calibrated light source. Your firm has no documented training or qualification for technicians and pharmacists who perform visual inspection.
Observation 12
The labels of your outsourcing facility's drug products are deficient.
Specifically,
A. The following info1mation is not found on your TPN diug product labels:
1. The statement, "This is a compounded diug."
2. The name, addi·ess, and phone number of the applicable facility.
3. The lot or batch number.
4. The established name of the diug.
5. The date that the drng was compounded.
6. The storage and handling instrnctions.
7. The statement, ''Not for resale."
8. The statement, "Office Use Only."
9. The active and inactive ingredients, identified by established name and the quantity or propo1iion ofeach ingredient.
B. The following info1mation is not found on some or all ofyour other dmg product labels.
1. The established name of the dmg.
2. The statement, "Office Use Only."
3. The active and inactive ingredients, identified by established name and the quantity or propo1iion ofeach ingredient.
Examples of diug product labels that do not contain this info1mation include, but are not limited to: ...
Observation 13
Your outsourcing facility has not submitted a report to FDA identifying a product compounded during the previous six months as required by section 503B(b)(2)(A).
Specifically, your compounded Total Parenteral Nutrition drug products were not identified on your most recent product report to FDA.
Inspection Sep 11, 2017 to Sep 20, 2017: 13 observations
- Firm on the cover
- Banner Pharmacy Services, LLC, 7300 W Detroit St, Chandler, AZ 85226-2410
- FEI number
- 3009422393
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 19701 Fairchild Irvine, CA 92612-2445
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
The quality control unit lacks the responsibility and authority to approve and reject all drug products.
Specifically,
Your firm failed to reject batches of sterile drug product that did not meet specifications for potency and particulate matter. The following mug products failed potency or paiiiculate matter testing and were released for distribution without adequate justification for invalidating failing test results:
Lot Number
Drug Product Date Released
Test Failed
062817S2 Magnesium Sulfate 1 Og added to
8/14/2017 Paiiiculate Matter
Lactated Ringers 250mL bag
071417Sl Norepinephrine Bitaiirate 8mg added to 0.9% Sodium Chloride 250mL bag
8/7/2017 Paiiiculate Matter
071417S2 Oxytocin 30 units added to 0.9% Sodium Chloride 500mL bag
8/23/2017 Potency
071717Sl Oxytocin 30 units added to 0.9% Sodium Chloride 500mL bag
8/23/2017 Potency
072017S4 Oxytocin 30 units added to 0.9% Sodium Chloride 500mL bag
8/23/2017 Potency
Observation 2
AMENDM ENT 1
Results of stability testing are not used in determining expiration dates.
Specifically,
Your firm's beyond-use dates (BUD) for sterile drug products are not assigned based on adequate stability testing. We reviewed stability study lots and observed OOS results for potency at one or more time points. Your firm assigned BUD based only on the passing results and disregarded the data from failing lots. For example:
• Oxytocin 30 units in 500ml NS cunent BUD of 119 days was based on one (1) product lot that had potency testing data within specification at all time points. However, three (3) additional lots on stability were out of specification for potency on days 36, 45, and 113.
• Lidocaine HCL 1 % buffered has a cunent BUD of45 days. However, while one (1) lot is still under testing, three (3) lots on stability were out of specification for potency on days 14, 45, and 60.
• Midazolam 100 MG (1 MG/ML) in 0.9% Sodium Chloride 100 ML Cassette cmTent BUD of 180 days was based on one (1) product lot that had potency testing data within specification at all time points. However, a second product lot on stability was out of specification for potency on day 120 of the study.
Observation 3
Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.
Specifically,
AMENDMENT 1
A. On September 13, 2016, your firm's <Redacted B4> testing of your cleanroom revealed there were <Redacted B4> leaks in 1 of the HEPA filters in the ISO 7 non-hazardous compounding room and 1 of the HEPA filters in the ISO 8 anteroom (gowning area). These leaks were documented again during the March 2017 <Redacted B4> certification testing. The two leaking HEPA filters were replaced on August 3, 2017. Your firm continued to manufacture sterile drug products from September 13, 2016 until August 3, 2017 and did not perform an investigation to determine if the leaking HEPA filters would compromise the sterility of your drug products.
B. Your firm's March 2017 cleamoom testing revealed the ISO 7 non-hazardous compounding room and anteroom (gowning area) did not meet the compendial pressure differential criteria of +0.02" of water. ...
Observation 4
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.
Specifically,
A. Your firm utilizes <Redacted B4> as a sporicidal cleaning disinfectant for <Redacted B4> cleaning of the ISO 5 laminar flow hoods, ISO 7 non-hazardous compounding room, ISO 8 anteroom (gowning room), and ISO 8 prep area. Your firm does not have scientific data to ensure the cleaning solution is effective as a sporicidal disinfectant.
AMENDMENT 1
B. Your fnm failed to perform cleaning in the ISO 7 non-hazardous compounding room after loss ofpositive pressure was observed as required per your SOP entitled, "Clean Room Downtime". The SOP states "fairflow or pressures out of range for greater than <Redacted B4> and "Down for less than <Redacted B4> clean". On the following days, your firm failed to follow procedures and perform cleaning required following a loss of pressure:
Cleaning Performed per Clean Room Downtime SOP May 25, 2017
Date Total time with lost pressure
Up to 6 hours and 12 minutes <Redacted B4> No (Cleaning with <Redacted B4>
AMENDM ENT 1
May 25, 2017
Up to 23 minutes <Redacted B4> No cleaning perfo1med ...
Observation 5
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.
Specifically,
A. On 9/11/2017, we observed Technicians <Redacted B4> performing aseptic processing of Lidocaine HCl, Oxytocin, and Vancomycin sterile drug products. We observed all <Redacted B4> technicians entering and leaving the ISO 5 Laminar Flow Hood (LFH) multiple times without sanitizing their gloved hands during the production of these sterile drug products.
B. We also observed all <Redacted B4> technicians introducing items such as 0.9% Sodium Chloride 500mL bags and J-Tip Syringes into the ISO 5 LFH without sanitizing the items or their outer packaging. In addition, your firm removes sterile items including Sodium Chloride 500mL bags and <Redacted B4> medication cassette reservoirs from their outer packaging in the ISO 8 prep room.
C. Not all of your technicians are qualified to perform aseptic drug production as only 2 out of a 4 total <Redacted B4> technicians have performed media fills that simulated the most complex or high volume compounding processes under normal operating conditions.
AMENDMENT 1 ...
Observation 6
Clothing of personnel engaged in the manufacturing and processing of drug products is not appropriate for the duties they perform.
Specifically,
AMENDM ENT 1
A. Your firm's gowning practices are inadequate to prevent contamination of sterile gowning materials. On 9/12/2017, we observed <Redacted B4> technicians in the anteroom gowning at the same time. The technicians were observed walking in the ISO 8 anteroom/gowning area with nonsterile shoe covers, donning sterile shoe covers, and then walking in the same area. We observed one technician who had donned a sterile gown bump into another technician who was in his scrubs. The technician did not re-gown. These technicians were gowning in order to perform <Redacted B4> cleaning operations for the ISO 7 non-hazardous compounding area. In addition, your fnm does not have an occupancy limit for the gowning anteroom.
B. Your fnm stores laundered scrnbs in the restrooms/changing rooms in front of the bathroom
stalls. On 9/18/2017, we observed the door to the scrnb storage unit in the men's restroom was opened. These scrnbs are worn by technicians underneath their sterile gowns while perfo1ming aseptic operations.
C. ...
Observation 7
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically,
A. Your firm does not perform non-viable particulate air monitoring in the ISO-classified areas during aseptic processing of sterile drug products. Non-viable air sampling is only conducted during <Redacted B4> certification of your cleanroom.
AMENDMENT 1
during aseptic processing of sterile chu g products. Non-viable air sampling is only conducted during[(6) (4) I certification of your cleanroom.
B. Your firm does not routinely monitor all ISO-classified areas in your facility. For example, the ISO 8 Prep Room <Redacted B4> is not sampled for viable air or viable surface. Also, non-viable air sampling for ISO 8 Prep Room <Redacted B4> is only performed during the <Redacted B4> certification. We observed sterile items, such as 0.9% sodium chloride injection USP 500 ml IV bags and <Redacted B4> medication cassette reservoirs were removed from their outer packaging in Prep Room <Redacted B4> and placed in a non-sterile plastic tote. These items were later transfered to the ISO 5 LFH for production without any fmi her sanitization of these items.
C. ...
Observation 8
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed. Specifically,
A. Your fnm's environmental monitoring excursion investigations are inadequate. For example, your fnm does not identify a probable root cause and does not assess product impact. Additionally, your investigations lack info1mation stating when the investigations were open, closed, and who perfo1med the investigations. Also, not all investigations have been reviewed and approved. Examples of investigations include but are not limited to:
AMENDMENT 1
a. On 5/26/2016, ISO 5 <Redacted B4> Hood <Redacted B4> viable active air was sampled and one (1) cfu was reported. On 6/13/2016, the contract testing lab notified your firm that speciation determined the colony to be Gram negative non-enteric bacteria and your firm's CAPA stated, "As per USP <797>, the gram negatives, yeast and mold are considered highly pathogenic and can be fatal to patients, especially immune compromised patients, receiving CSP's". ...
Observation 9
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications prior to release.
Specifically,
Your firm produces non-sterile oral V ancomycin HCL 250 mg/10 ml and GI cocktail oral suspension 30 ml (20 ml Maalox plus equiv + 10 ml 2% Lidocaine) for office use. Your firm has not established
AMENDMENT 1
acceptable levels of microorganisms and has not tested these finished drug products for acceptable levels and the presence of objectionable microorganisms per compendia! requirements.
Observation 10
Test procedures relative to appropriate laboratory testing for pyrogens are not written and followed.
Specifically, your firm's endotoxin testing is deficient in that only five (5) out of a total of fifteen (15) sterile compounded drug products have complete endotoxin method validations per compendial requirements.
Observation 11
Determinations of conformance to appropriate written specifications for acceptance are deficient for drug products.
Specifically,
Your firm does not perform 100% visual inspection of all sterile drug products. Your firm's technicians/pharmacists perform cursory batch inspection followed by detailed visual inspections on <Redacted B4> in that batch. Visual inspections are performed without the use of contrasting backgrounds and a calibrated light source. Your firm has no documented training or qualification for technicians and pharmacists who perform visual inspection.
Observation 12
The labels of your outsourcing facility's drug products are deficient.
AM ENDMENT 1
Specifically,
A. The following info1mation is not found on your TPN dtug product labels:
1. The statement, "This is a compounded dtug."
2. The name, addt·ess, and phone number of the applicable facility.
3. The lot or batch number.
4. The established name of the dtug.
5. The date that the drng was compounded.
6. The storage and handling instrnctions.
7. The statement, ''Not for resale."
8. The statement, "Office Use Only."
9. The active and inactive ingredients, identified by established name and the quantity or propo1iion ofeach ingredient.
B. The following info1mation is not found on some or all ofyour other dt11g product labels.
1. The established name of the dtug.
2. The statement, "Office Use Only."
3. The active and inactive ingredients, identified by established name and the quantity or propo1iion ofeach ingredient.
AMENDMENT 1
Examples of diug product labels that do not contain this infonnation include, but are not limited to: ...
Observation 13
AMENDM ENT 1
Your outsourcing facility has not submitted a report to FDA identifying a product compounded during the previous six months as required by section 503B(b )(2)(A).
Specifically, your compounded Total Parenteral Nutrition drug products were not identified on your most recent product report to FDA.
Linked 483s whose text is not shown
- Jul 23, 2015: FDA document 91503: its numbered observations could not be read reliably from the PDF text.
State board of pharmacy records
State board of pharmacy records for Arizona are not checked: the board’s website, which hosts its license verification and board orders, answers automated requests with a bot challenge, and this index does not work around blocks.
This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
Records last pulled Nov 15, 2026. Every entry links to the original public record.